文献速递腹部MR

MRI LI-RADS 2018版特征及临床病理因素对甲胎蛋白阴性肝细胞癌的预后评估价值

Prognostic performance of MRI LI-RADS version 2018 features and clinical-pathological factors in alpha-fetoprotein-negative hepatocellular carcinoma.
PubMed 文献 · Abdom Radiol (NY) · 2024-04-20

该回顾性研究纳入169例接受术前MRI和肝切除术的甲胎蛋白阴性(≤20 ng/ml)肝细胞癌患者(推导集:验证集=118:51),基于Cox回归识别的6个风险因素构建预后模型,推导集和验证集C-index分别为0.705和0.674,模型预后预测能力优于两种传统分期系统,可将患者分层为预后显著不同的高风险组和低风险组(p < 0.05)。

要点

  • LI-RADS分类、肿块内血产物、微血管侵犯、肿瘤大小、肝硬化和白蛋白-胆红素分级与无复发生存相关。
  • 基于上述6个因素构建的预后模型在推导集和验证集C-index分别为0.705和0.674。
  • 该模型预后预测能力优于传统分期系统,可将AFP阴性HCC患者分层为预后显著不同的高、低风险组(p < 0.05)。

核心结论

  • 整合LI-RADS分类、肿块内血产物、微血管侵犯、肿瘤大小、肝硬化和白蛋白-胆红素分级的预后模型可能作为细化AFP阴性肝细胞癌患者风险分层的有效工具。

研究设计与样本

  • 回顾性研究,纳入2015年1月至2020年8月间接受术前MRI和肝切除术的169例AFP阴性(≤20 ng/ml)肝细胞癌患者,推导集与验证集比例为118:51,采用Cox回归分析识别风险因素并构建预后模型,与两种传统分期系统比较预测性能和区分能力。

关键影像表现/征象

  • 肿块内血产物是与无复发生存相关的风险因素之一。
  • LI-RADS分类是与无复发生存相关的风险因素之一。

诊断标准与关键数值

  • AFP阴性定义为≤20 ng/ml。
  • 预后模型在推导集的C-index为0.705,在验证集的C-index为0.674。
  • 模型可将AFP阴性肝细胞癌患者分层为高风险组和低风险组,两组结局差异显著(p < 0.05)。

临床应用与阅片要点

  • 阅片时可关注LI-RADS分类和肿块内血产物,二者被纳入AFP阴性肝细胞癌的预后模型。
  • 该模型可能有助于细化AFP阴性肝细胞癌患者的风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the role of the magnetic resonance imaging (MRI) Liver Imaging Reporting and Data System (LI-RADS) version 2018 features and clinical-pathological factors for predicting the prognosis of alpha-fetoprotein (AFP)-negative (≤ 20 ng/ml) hepatocellular carcinoma (HCC) patients, and to compare with other traditional staging systems.

METHODS: We retrospectively enrolled 169 patients with AFP-negative HCC who received preoperative MRI and hepatectomy between January 2015 and August 2020 (derivation dataset:validation dataset = 118:51). A prognostic model was constructed using the risk factors identified via Cox regression analysis. Predictive performance and discrimination capability were evaluated and compared with those of two traditional staging systems.

RESULTS: Six risk factors, namely the LI-RADS category, blood products in mass, microvascular invasion, tumor size, cirrhosis, and albumin-bilirubin grade, were associated with recurrence-free survival. The prognostic model constructed using these factors achieved C-index of 0.705 and 0.674 in the derivation and validation datasets, respectively. Furthermore, the model performed better in predicting patient prognosis than traditional staging systems. The model effectively stratified patients with AFP-negative HCC into high- and low-risk groups with significantly different outcomes (p < 0.05).

CONCLUSION: A prognostic model integrating the LI-RADS category, blood products in mass, microvascular invasion, tumor size, cirrhosis, and albumin-bilirubin grade may serve as a valuable tool for refining risk stratification in patients with AFP-negative HCC.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Wang L, Feng B, Liang M, et al. Prognostic performance of MRI LI-RADS version 2018 features and clinical-pathological factors in alpha-fetoprotein-negative hepatocellular carcinoma. Abdom Radiol (NY). 2024. PMID: 38642093. doi:10.1007/s00261-024-04278-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。